+919405117673

Orthopedict

Denosurel 120mg Injection

In stock

Description

Denosurel 120mg Injection is a prescription biological medicine containing Denosumab 120mg as its active ingredient. It belongs to a class of medicines known as monoclonal antibodies and is designed to target the Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL), a protein involved in the regulation of bone breakdown.

Denosumab works by binding to RANKL and preventing its interaction with the RANK receptor on osteoclasts and their precursor cells. Osteoclasts are responsible for bone resorption, a natural process through which old bone tissue is broken down. By inhibiting this activity, Denosumab helps reduce excessive bone destruction and supports the management of certain bone-related complications associated with cancer.

Denosurel 120mg Injection is used in specialist medical care, particularly in oncology settings, where maintaining bone health and reducing skeletal complications are important aspects of patient management.

Composition and Product Details

Product Name: Denosurel 120mg Injection

Active Ingredient: Denosumab

Strength: 120mg

Dosage Form: Injection

Therapeutic Category: Monoclonal Antibody

Pharmacological Class: RANK Ligand (RANKL) Inhibitor

Route of Administration: Subcutaneous

Manufacturer/Marketer: Reliance Formulation Pvt. Ltd.

Prescription Status: Prescription Medicine

The exact presentation, excipients, vial volume and pack configuration should be confirmed against the manufacturer's approved product packaging and prescribing information.

Therapeutic Applications

Denosumab 120mg is used in the management of specific bone-related conditions. Its established clinical applications include:

Bone Metastases: Denosumab is used to help prevent skeletal-related events in patients with advanced cancers that have spread to the bones. These complications may include pathological fractures, spinal cord compression and the need for radiation therapy or surgery involving bone.

Multiple Myeloma: The 120mg formulation is also indicated in certain patients with multiple myeloma to reduce the risk of skeletal-related complications associated with the disease.

Giant Cell Tumour of Bone: Denosumab may be prescribed for adults and skeletally mature adolescents with unresectable giant cell tumours or cases where surgical removal could result in significant complications.

Hypercalcemia of Malignancy: Denosumab is also used for certain cases of cancer-associated hypercalcemia that have not responded adequately to bisphosphonate treatment.

The suitability of treatment depends on the patient's diagnosis, clinical condition and the treating specialist's assessment.

Mechanism of Action

Denosumab acts by selectively binding to RANKL, a signalling protein essential for osteoclast formation, activation and survival. By blocking RANKL activity, it reduces osteoclast-mediated bone resorption.

This mechanism helps decrease excessive bone breakdown and supports the prevention of skeletal complications in patients with certain malignancies affecting bone tissue.

Administration and Dosage Information

Denosurel 120mg Injection should be administered by a qualified healthcare professional under appropriate medical supervision. The injection is intended for subcutaneous administration and must not be administered intravenously or intramuscularly.

The dosing schedule depends on the medical indication. For certain oncology indications, Denosumab 120mg is administered every four weeks. Some conditions require additional doses during the initial treatment month.

Calcium levels should be assessed and monitored during treatment. Calcium and vitamin D supplementation may be required according to the treating physician's recommendations.

Storage and Handling

Denosumab 120mg injection products generally require refrigerated storage between 2°C and 8°C. The medicine should be protected from direct light and should not be frozen or vigorously shaken.

Temperature-controlled handling and appropriate packaging are important for maintaining product quality during storage and pharmaceutical distribution. Always follow the specific storage instructions printed on the Denosurel manufacturer's packaging.

Product Safety and Medical Considerations

Denosumab treatment requires appropriate medical supervision. Important safety considerations include hypocalcemia, osteonecrosis of the jaw, hypersensitivity reactions and atypical femoral fractures. Patients with severe kidney impairment may have an increased risk of developing serious hypocalcemia.

Pre-existing low calcium levels should be corrected before treatment begins. Dental assessment and appropriate oral hygiene are also important considerations during therapy.

Denosurel 120mg Injection should only be used according to an authorised healthcare professional's prescription and the applicable product information.